Rivaroxiban effective in treating COVID 19 patients: MICHELLE Trial

Published On 2022-02-08 12:23 GMT   |   Update On 2022-02-08 13:53 GMT
Advertisement

The covid pandemic has rained its havoc in the entire world.  Millions of patients died and many more were discharged worldwide. Excessive thrombosis was the designated culprit for the morbidity and mortality. MICELLE trial was conducted to find out whether rivaroxiban which is a direct anticoagulant is useful in patients after hospitalization for covid-19 for improving their clinical outcomes without bleeding. This was a landmark trial.

Advertisement

 The primary outcome reported symptomatic venous thromboembolism, venous thromboembolism-related death, bilateral venous thromboembolism, symptomatic arterial thromboembolism, myocardial infarction, non hemorrhagic stroke, major adverse limb event, or cardiovascular death at 35 days, was 3.14% in the rivaroxaban group compared with 9.43% in the control group. Among patients discharged after COVID-19 infection, rivaroxaban for 35 days was beneficial.

The trials main purpose was to evaluate rivaroxaban compared with control among patients discharged after hospitalization for coronavirus disease infection. Over 160 participants discharged after COVID-19 infection were randomized to rivaroxaban 10 mg daily, vs control. Rivaroxaban was associated with a reduction in clinical events without increasing major bleeding.  

Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News